Mouse Anti-Human Alpha Synuclein N-terminal Monoclonal IgG1 Antibody
Alpha-synuclein is a presynaptic neuronal protein implicated in the pathogenesis of several neurodegenerative diseases, including Parkinson’s disease and dementia with Lewy bodies. Among its structural domains, the N-terminal region plays a pivotal role in membrane binding, conformational dynamics, and aggregation behavior. Post-translational modifications, particularly C-terminal truncations, significantly influence alpha-synuclein’s aggregation propensity and neurotoxicity (1).
C-terminally truncated alpha-synuclein species are highly enriched in pathological inclusions such as Lewy bodies and Lewy neurites. These truncated forms exhibit accelerated fibrillization and enhanced prion-like propagation in cellular and animal models of Parkinson’s disease, underscoring their pathogenic relevance (1). Importantly, such truncations can alter the structural conformation of alpha-synuclein, masking epitopes commonly targeted by antibodies, including those recognizing phosphorylated serine 129 (pSer129) .
This epitope masking has critical implications for research and diagnostics. Antibodies specific to pSer129 may fail to detect C-terminally truncated alpha-synuclein, potentially underestimating the burden of pathogenic species in tissue samples. Therefore, careful selection of antibodies that target the N-terminal region is essential for accurate detection and quantification of disease-relevant alpha-synuclein conformers (3).
Understanding the structural and functional roles of the alpha-synuclein N-terminus is vital for elucidating disease mechanisms and developing targeted therapeutic strategies in synucleinopathies.
This Mouse Anti-Human Alpha Synuclein N-terminal Monoclonal IgG1 Antibody is manufactured in Canada by StressMarq.
